Expression and clinical significance of CXCR5/CXCL13 in human non‑small cell lung carcinoma

Singh,Rajesh; Gupta,Pranav; Kloecker,Goetz H.; Singh,Shailesh; Lillard Jr,James W.

doi:10.3892/ijo.2014.2688

Expression and clinical significance of CXCR5/CXCL13 in human non‑small cell lung carcinoma

Authors:
- Rajesh Singh
- Pranav Gupta
- Goetz H. Kloecker
- Shailesh Singh
- James W. Lillard Jr
View Affiliations

Affiliations: Department of Microbiology, Biochemistry and Immunology, Morehouse School of Medicine, Atlanta, GA 30310‑1495, USA, James Graham Brown Cancer Center, University of Louisville, KY 40202, USA
Published online on: September 30, 2014 https://doi.org/10.3892/ijo.2014.2688
Pages: 2232-2240
Copyright: © Singh et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

CXCR5 and/or CXCL13 expression is elevated in certain carcinomas and lymphomas. To determine if these factors are involved in progression of non‑small cell lung cancer (LuCa), we evaluated their expression in patients with various forms of this disease. Lung biopsies from patients with non‑neoplastic cells (n=8), squamous cell carcinoma (SCC; n=24), or adenocarcinoma (AC; n=54) were stained for CXCR5. Histopathological analysis of these samples showed significantly higher expression of CXCR5 (p<0.001) in carcinomas (i.e., SCCs and ACs) relative to non‑neoplastic lung tissue. Nuclear and membrane CXCR5 intensities were highest in ACs, with median values of 185 and 130, respectively, followed by SCCs with median values of 170 and 110, respectively. The lowest nuclear and membrane expressions of CXCR5 were found in non‑neoplastic tissues, having median values of 142 and 90, respectively. Sera from SCC patients (n=17), AC patients (n=14), and healthy controls (n=9) were tested for the presence of CXCL13. Serum CXCL13 levels in LuCa patients were higher than in healthy controls. CXCR5 expression in cell lines of human non‑small cell lung carcinoma (NCI‑H1915) and small cell lung carcinoma (SW‑1271) were evaluated by flow cytometry. CXCR5 expression was higher in NCI‑H1915 cells relative to SW‑1271 cells. The functional significance of CXCR5 expression was tested in a migration assay. In response to CXCL13, more NCI‑H1915 cells migrated than SW‑1271 cells. These findings suggest that the CXCR5‑CXCL13 axis influences LuCa progression. After validation in larger patient groups, CXCR5 and CXCL13 may prove useful as biomarkers for LuCa. Correspondingly, blockade of this axis could serve as an effective therapy for LuCa.

View Figures

View References

1	Esposito L, Conti D, Ailavajhala R, Khalil N and Giordano A: Lung cancer: are we up to the challenge? Curr Genomics. 11:513–518. 2010. View Article : Google Scholar : PubMed/NCBI
2	Molina JR, Yang P, Cassivi SD, Schild SE and Adjei AA: Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 83:584–594. 2008. View Article : Google Scholar : PubMed/NCBI
3	Baird AM, Gray SG and O’Byrne KJ: Epigenetics underpinning the regulation of the CXC (ELR+) chemokines in non-small cell lung cancer. PLoS One. 6:e145932011. View Article : Google Scholar : PubMed/NCBI
4	Lazennec G and Richmond A: Chemokines and chemokine receptors: new insights into cancer-related inflammation. Trends Mol Med. 16:133–144. 2010. View Article : Google Scholar : PubMed/NCBI
5	Su L, Zhang J, Xu H, Wang Y, Chu Y, Liu R and Xiong S: Differential expression of CXCR4 is associated with the meta-static potential of human non-small cell lung cancer cells. Clin Cancer Res. 11:8273–8280. 2005. View Article : Google Scholar : PubMed/NCBI
6	Burger JA and Kipps TJ: CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood. 107:1761–1767. 2006. View Article : Google Scholar : PubMed/NCBI
7	Bürkle A, Niedermeier M, Schmitt-Gräff A, Wierda WG, Keating MJ and Burger JA: Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia. Blood. 110:3316–3325. 2007.PubMed/NCBI
8	Hussain SK, Zhu W, Chang SC, et al: Serum levels of the chemokine CXCL13, genetic variation in CXCL13 and its receptor CXCR5, and HIV-associated non-Hodgkin B-Cell lymphoma risk. Cancer Epidemiol Biomarkers Prev. 22:295–307. 2013. View Article : Google Scholar : PubMed/NCBI
9	Kurtova AV, Tamayo AT, Ford RJ and Burger JA: Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting. Blood. 113:4604–4613. 2009. View Article : Google Scholar : PubMed/NCBI
10	Chan CC, Shen D, Hackett JJ, Buggage RR and Tuaillon N: Expression of chemokine receptors, CXCR4 and CXCR5, and chemokines, BLC and SDF-1, in the eyes of patients with primary intraocular lymphoma. Ophthalmology. 110:421–426. 2003. View Article : Google Scholar : PubMed/NCBI
11	Singh S, Singh R, Singh UP, et al: Clinical and biological significance of CXCR5 expressed by prostate cancer specimens and cell lines. Int J Cancer. 125:2288–2295. 2009. View Article : Google Scholar : PubMed/NCBI
12	Singh S, Singh R, Sharma PK, et al: Serum CXCL13 positively correlates with prostatic disease, prostate-specific antigen and mediates prostate cancer cell invasion, integrin clustering and cell adhesion. Cancer Lett. 283:29–35. 2009. View Article : Google Scholar
13	Panse J, Friedrichs K, Marx A, et al: Chemokine CXCL13 is overexpressed in the tumour tissue and in the peripheral blood of breast cancer patients. Br J Cancer. 99:930–938. 2008. View Article : Google Scholar : PubMed/NCBI
14	Del Grosso F, Coco S, Scaruffi P, et al: Role of CXCL13-CXCR5 crosstalk between malignant neuroblastoma cells and Schwannian stromal cells in neuroblastic tumors. Mol Cancer Res. 9:815–823. 2011.PubMed/NCBI
15	Yuvaraj S, Griffin AC, Sundaram K, Kirkwood KL, Norris JS and Reddy SV: A novel function of CXCL13 to stimulate RANK ligand expression in oral squamous cell carcinoma cells. Mol Cancer Res. 7:1399–1407. 2009. View Article : Google Scholar : PubMed/NCBI
16	Airoldi I, Cocco C, Morandi F, Prigione I and Pistoia V: CXCR5 may be involved in the attraction of human metastatic neuroblastoma cells to the bone marrow. Cancer Immunol Immunother. 57:541–548. 2008. View Article : Google Scholar : PubMed/NCBI
17	El Haibi CP, Sharma PK, Singh R, Johnson PR, Suttles J, Singh S and Lillard JW Jr: PI3Kp110-, Src-, FAK-dependent and DOCK2-independent migration and invasion of CXCL13-stimulated prostate cancer cells. Mol Cancer. 9:852010.PubMed/NCBI
18	El-Haibi CP, Singh R, Sharma PK, Singh S and Lillard JW Jr: CXCL13 mediates prostate cancer cell proliferation through JNK signalling and invasion through ERK activation. Cell Prolif. 44:311–319. 2011. View Article : Google Scholar : PubMed/NCBI
19	Iwakiri S, Mino N, Takahashi T, et al: Higher expression of chemokine receptor CXCR7 is linked to early and metastatic recurrence in pathological stage I nonsmall cell lung cancer. Cancer. 115:2580–2593. 2009. View Article : Google Scholar : PubMed/NCBI
20	Rollins BJ: Chemokines. Blood. 90:909–928. 1997.PubMed/NCBI
21	Taub DD: Chemokine-leukocyte interactions. The voodoo that they do so well. Cytokine Growth Factor Rev. 7:355–376. 1996. View Article : Google Scholar : PubMed/NCBI
22	Spano JP, Andre F, Morat L, et al: Chemokine receptor CXCR4 and early-stage non-small cell lung cancer: pattern of expression and correlation with outcome. Ann Oncol. 15:613–617. 2004. View Article : Google Scholar : PubMed/NCBI
23	Zhu YM, Webster SJ, Flower D and Woll PJ: Interleukin-8/CXCL8 is a growth factor for human lung cancer cells. Br J Cancer. 91:1970–1976. 2004. View Article : Google Scholar : PubMed/NCBI
24	Phillips RJ, Burdick MD, Lutz M, Belperio JA, Keane MP and Strieter RM: The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases. Am J Respir Crit Care Med. 167:1676–1686. 2003. View Article : Google Scholar : PubMed/NCBI
25	Saintigny P, Massarelli E, Lin S, et al: CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma. Cancer Res. 73:571–582. 2013. View Article : Google Scholar : PubMed/NCBI
26	Chen JJ, Yao PL, Yuan A, et al: Up-regulation of tumor interleukin-8 expression by infiltrating macrophages: its correlation with tumor angiogenesis and patient survival in non-small cell lung cancer. Clin Cancer Res. 9:729–737. 2003.PubMed/NCBI
27	Ichinose Y, Yano T, Asoh H, Yokoyama H, Yoshino I and Katsuda Y: Prognostic factors obtained by a pathologic examination in completely resected non-small-cell lung cancer. An analysis in each pathologic stage. J Thorac Cardiovasc Surg. 110:601–605. 1995. View Article : Google Scholar : PubMed/NCBI
28	Suzuki K, Nagai K, Yoshida J, Nishimura M, Takahashi K, Yokose T and Nishiwaki Y: Conventional clinicopathologic prognostic factors in surgically resected nonsmall cell lung carcinoma. A comparison of prognostic factors for each pathologic TNM stage based on multivariate analyses. Cancer. 86:1976–1984. 1999. View Article : Google Scholar